A 58-year-old male from Delhi presents with a 5-day history of fever (38.5°C), dry cough, and dyspnea. He reports loss of taste and smell for 2 days. On examination, SpO₂ is 88% on room air, respiratory rate 28/min, and bilateral crackles on auscultation. His wife tested positive for COVID-19 3 days ago. Chest X-ray shows bilateral ground-glass opacities. RT-PCR for SARS-CoV-2 is positive. His D-dimer is 1.2 μg/mL (normal

Question

A 58-year-old male from Delhi presents with a 5-day history of fever (38.5°C), dry cough, and dyspnea. He reports loss of taste and smell for 2 days. On examination, SpO₂ is 88% on room air, respiratory rate 28/min, and bilateral crackles on auscultation. His wife tested positive for COVID-19 3 days ago. Chest X-ray shows bilateral ground-glass opacities. RT-PCR for SARS-CoV-2 is positive. His D-dimer is 1.2 μg/mL (normal <0.5), ferritin 450 ng/mL (normal <200), and CRP 95 mg/L (normal <10). What is the most appropriate next step in management?

Accepted Answer

B. Admit for oxygen therapy, consider remdesivir, monitor inflammatory markers, and assess for thromboprophylaxis. ## Clinical Assessment

This patient presents with **moderate COVID-19** based on:
- Hypoxemia (SpO₂ 88%) with respiratory distress (RR 28)
- Bilateral pneumonia on imaging (ground-glass opacities)
- Elevated inflammatory markers (ferritin, CRP, D-dimer)
- Anosmia/ageusia (typical early feature of SARS-CoV-2)

## Management Principles for Moderate COVID-19

**Key Point:** Moderate COVID-19 (SpO₂ 90–93%, bilateral pneumonia, elevated inflammatory markers) requires hospitalization for oxygen therapy and monitoring for progression.

### Therapeutic Approach

| Component | Rationale |
|-----------|----------|
| **Oxygen therapy** | SpO₂ 88% mandates supplemental O₂ to target ≥94% |
| **Remdesivir** | Antiviral nucleotide analogue; reduces time to recovery in moderate-to-severe disease [cite:WHO COVID-19 Guidelines 2023] |
| **Inflammatory marker monitoring** | Elevated ferritin and CRP predict progression to severe disease; serial monitoring guides escalation |
| **Thromboprophylaxis** | Elevated D-dimer + hospitalization = VTE risk; consider LMWH |
| **Corticosteroids** | Reserved for severe disease (SpO₂ <90% or rapid deterioration); not indicated in moderate disease without hypoxemia |

**High-Yield:** The presence of **bilateral pneumonia + hypoxemia + elevated inflammatory markers** defines the moderate category requiring hospitalization and antiviral therapy.

**Clinical Pearl:** Anosmia/ageusia in the first 2 days is a strong predictor of COVID-19 and correlates with early viral load peak; these patients often progress rapidly if inflammatory markers are elevated.

## Why This Patient Needs Admission

1. **Hypoxemia** (SpO₂ 88%) — cannot be managed safely in outpatient setting
2. **Bilateral pneumonia** — risk of rapid deterioration
3. **Elevated D-dimer** — thrombotic risk; requires anticoagulation
4. **Ferritin and CRP elevation** — markers of cytokine-mediated inflammation; remdesivir + monitoring indicated

**Mnemonic: MODERATE COVID = Admit + Antivirals + Assess**
- **A**dmit for oxygen
- **A**ntiviral (remdesivir)
- **A**ssess inflammatory trajectory
- **S**creen for thrombosis risk

Answer

A. Prescribe azithromycin and hydroxychloroquine as outpatient therapy with home isolation

Answer

C. Start low-flow oxygen, monitor for 48 hours, and discharge if SpO₂ remains >94%

Answer

D. Initiate mechanical ventilation immediately and start high-dose corticosteroids

Explanation

Practice similar questions